ID   CATL1_HUMAN             Reviewed;         333 AA.
AC   P07711; Q6IAV1; Q96QJ0;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1989, sequence version 2.
DT   02-OCT-2024, entry version 242.
DE   RecName: Full=Procathepsin L {ECO:0000305};
DE            EC=3.4.22.15 {ECO:0000269|PubMed:9468501};
DE   AltName: Full=Cathepsin L1 {ECO:0000305};
DE   AltName: Full=Major excreted protein;
DE            Short=MEP;
DE   Contains:
DE     RecName: Full=Cathepsin L;
DE   Contains:
DE     RecName: Full=Cathepsin L heavy chain;
DE   Contains:
DE     RecName: Full=Cathepsin L light chain;
DE   Flags: Precursor;
GN   Name=CTSL {ECO:0000312|HGNC:HGNC:2537}; Synonyms=CTSL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3421948; DOI=10.1042/bj2530303;
RA   Gal S., Gottesman M.M.;
RT   "Isolation and sequence of a cDNA for human pro-(cathepsin L).";
RL   Biochem. J. 253:303-306(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2835398; DOI=10.1172/jci113497;
RA   Joseph L.J., Chang L.C., Stamenkovich D., Sukhatme V.P.;
RT   "Complete nucleotide and deduced amino acid sequences of human and murine
RT   preprocathepsin L. An abundant transcript induced by transformation of
RT   fibroblasts.";
RL   J. Clin. Invest. 81:1621-1629(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 114-288 AND 292-333.
RX   PubMed=3342889; DOI=10.1016/0014-5793(88)80028-0;
RA   Ritonja A., Popovic T., Kotnik M., Machleidt W., Turk V.;
RT   "Amino acid sequences of the human kidney cathepsins H and L.";
RL   FEBS Lett. 228:341-345(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 113-154.
RX   PubMed=3550705; DOI=10.1093/nar/15.7.3186;
RA   Joseph L.J., Lapid S., Sukhatme V.P.;
RT   "The major ras induced protein in NIH3T3 cells is cathepsin L.";
RL   Nucleic Acids Res. 15:3186-3186(1987).
RN   [9]
RP   PROTEIN SEQUENCE OF 114-154 AND 292-333.
RX   PubMed=3545185; DOI=10.1042/bj2400373;
RA   Mason R.W., Walker J.E., Northrop F.D.;
RT   "The N-terminal amino acid sequences of the heavy and light chains of human
RT   cathepsin L. Relationship to a cDNA clone for a major cysteine proteinase
RT   from a mouse macrophage cell line.";
RL   Biochem. J. 240:373-377(1986).
RN   [10]
RP   FUNCTION, PROTEOLYTICAL CLEAVAGE, MUTAGENESIS OF CYS-138, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, AND ACTIVE
RP   SITE.
RX   PubMed=9468501; DOI=10.1074/jbc.273.8.4478;
RA   Menard R., Carmona E., Takebe S., Dufour E., Plouffe C., Mason P.,
RA   Mort J.S.;
RT   "Autocatalytic processing of recombinant human procathepsin L. Contribution
RT   of both intermolecular and unimolecular events in the processing of
RT   procathepsin L in vitro.";
RL   J. Biol. Chem. 273:4478-4484(1998).
RN   [11]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10716919; DOI=10.1093/emboj/19.6.1187;
RA   Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., Mothes W.;
RT   "Secreted cathepsin L generates endostatin from collagen XVIII.";
RL   EMBO J. 19:1187-1194(2000).
RN   [12]
RP   GLYCOSYLATION AT ASN-221.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15099520; DOI=10.1016/s1097-2765(04)00209-6;
RA   Goulet B., Baruch A., Moon N.S., Poirier M., Sansregret L.L., Erickson A.,
RA   Bogyo M., Nepveu A.;
RT   "A cathepsin L isoform that is devoid of a signal peptide localizes to the
RT   nucleus in S phase and processes the CDP/Cux transcription factor.";
RL   Mol. Cell 14:207-219(2004).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-221.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J.,
RA   Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [15]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=16081529; DOI=10.1073/pnas.0505577102;
RA   Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L.,
RA   Bates P.;
RT   "Inhibitors of cathepsin L prevent severe acute respiratory syndrome
RT   coronavirus entry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:11876-11881(2005).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=16339146; DOI=10.1074/jbc.m508381200;
RA   Huang I.C., Bosch B.J., Li F., Li W., Lee K.H., Ghiran S., Vasilieva N.,
RA   Dermody T.S., Harrison S.C., Dormitzer P.R., Farzan M., Rottier P.J.,
RA   Choe H.;
RT   "SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to
RT   infect ACE2-expressing cells.";
RL   J. Biol. Chem. 281:3198-3203(2006).
RN   [17]
RP   FUNCTION (MICROBIAL INFECTION), AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18562523; DOI=10.1128/jvi.00415-08;
RA   Bosch B.J., Bartelink W., Rottier P.J.;
RT   "Cathepsin L functionally cleaves the severe acute respiratory syndrome
RT   coronavirus class I fusion protein upstream of rather than adjacent to the
RT   fusion peptide.";
RL   J. Virol. 82:8887-8890(2008).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-221.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION), AND ACTIVITY REGULATION.
RX   PubMed=26953343; DOI=10.1074/jbc.m116.716100;
RA   Zhou N., Pan T., Zhang J., Li Q., Zhang X., Bai C., Huang F., Peng T.,
RA   Zhang J., Liu C., Tao L., Zhang H.;
RT   "Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late
RT   Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East
RT   Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory
RT   Syndrome Coronavirus (SARS-CoV).";
RL   J. Biol. Chem. 291:9218-9232(2016).
RN   [23]
RP   ACTIVITY REGULATION.
RX   PubMed=30425301; DOI=10.1038/s41436-018-0355-3;
RA   van den Bogaard E.H.J., van Geel M., van Vlijmen-Willems I.M.J.J.,
RA   Jansen P.A.M., Peppelman M., van Erp P.E.J., Atalay S., Venselaar H.,
RA   Simon M.E.H., Joosten M., Schalkwijk J., Zeeuwen P.L.J.M.;
RT   "Deficiency of the human cysteine protease inhibitor cystatin M/E causes
RT   hypotrichosis and dry skin.";
RL   Genet. Med. 21:1559-1567(2019).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor.";
RL   Cell 181:1-10(2020).
RN   [25]
RP   ACTIVITY REGULATION.
RX   PubMed=32361028; DOI=10.1016/j.ijantimicag.2020.106004;
RA   Smieszek S.P., Przychodzen B.P., Polymeropoulos M.H.;
RT   "Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19
RT   treatment.";
RL   Int. J. Antimicrob. Agents 55:106004-106004(2020).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   "Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV.";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=32855215; DOI=10.1126/science.abb3753;
RA   Bruchez A., Sha K., Johnson J., Chen L., Stefani C., McConnell H.,
RA   Gaucherand L., Prins R., Matreyek K.A., Hume A.J., Muehlberger E.,
RA   Schmidt E.V., Olinger G.G., Stuart L.M., Lacy-Hulbert A.;
RT   "MHC class II transactivator CIITA induces cell resistance to Ebola virus
RT   and SARS-like coronaviruses.";
RL   Science 370:241-247(2020).
RN   [28]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   "TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells.";
RL   EMBO J. 40:1-20(2021).
RN   [29] {ECO:0007744|PDB:1CJL, ECO:0007744|PDB:1CS8}
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 18-333.
RX   PubMed=8896443; DOI=10.1002/j.1460-2075.1996.tb00934.x;
RA   Coulombe R., Grochulski P., Sivaraman J., Menard R., Mort J.S., Cygler M.;
RT   "Structure of human procathepsin L reveals the molecular basis of
RT   inhibition by the prosegment.";
RL   EMBO J. 15:5492-5503(1996).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 114-333.
RX   PubMed=9141479; DOI=10.1016/s0014-5793(97)00216-0;
RA   Fujishima A., Imai Y., Nomura T., Fujisawa Y., Yamamoto Y., Sugarawa T.;
RT   "The crystal structure of human cathepsin L complexed with E-64.";
RL   FEBS Lett. 407:47-50(1997).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 18-333.
RA   Cygler M., Coulombe R.;
RL   Submitted (AUG-1999) to the PDB data bank.
CC   -!- FUNCTION: Thiol protease important for the overall degradation of
CC       proteins in lysosomes (Probable). Plays a critical for normal cellular
CC       functions such as general protein turnover, antigen processing and bone
CC       remodeling. Involved in the solubilization of cross-linked
CC       TG/thyroglobulin and in the subsequent release of thyroid hormone
CC       thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the
CC       thyroid follicle lumen (By similarity). In neuroendocrine chromaffin
CC       cells secretory vesicles, catalyzes the prohormone proenkephalin
CC       processing to the active enkephalin peptide neurotransmitter (By
CC       similarity). In thymus, regulates CD4(+) T cell positive selection by
CC       generating the major histocompatibility complex class II (MHCII) bound
CC       peptide ligands presented by cortical thymic epithelial cells. Also
CC       mediates invariant chain processing in cortical thymic epithelial cells
CC       (By similarity). Major elastin-degrading enzyme at neutral pH.
CC       Accumulates as a mature and active enzyme in the extracellular space of
CC       antigen presenting cells (APCs) to regulate degradation of the
CC       extracellular matrix in the course of inflammation (By similarity).
CC       Secreted form generates endostatin from COL18A1 (PubMed:10716919).
CC       Critical for cardiac morphology and function. Plays an important role
CC       in hair follicle morphogenesis and cycling, as well as epidermal
CC       differentiation (By similarity). Required for maximal stimulation of
CC       steroidogenesis by TIMP1 (By similarity).
CC       {ECO:0000250|UniProtKB:P06797, ECO:0000250|UniProtKB:P07154,
CC       ECO:0000250|UniProtKB:P25975, ECO:0000269|PubMed:10716919,
CC       ECO:0000305}.
CC   -!- FUNCTION: (Microbial infection) In cells lacking TMPRSS2 expression,
CC       facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via
CC       a slow acid-activated route with the proteolysis of coronavirus spike
CC       (S) glycoproteins in lysosome for entry into host cell
CC       (PubMed:16339146, PubMed:18562523, PubMed:32142651, PubMed:32221306).
CC       Proteolysis within lysosomes is sufficient to activate membrane fusion
CC       by coronaviruses SARS-CoV and EMC (HCoV-EMC) S as well as Zaire
CC       ebolavirus glycoproteins (PubMed:16081529, PubMed:18562523,
CC       PubMed:26953343). {ECO:0000269|PubMed:16081529,
CC       ECO:0000269|PubMed:16339146, ECO:0000269|PubMed:18562523,
CC       ECO:0000269|PubMed:26953343, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32221306, ECO:0000269|PubMed:32855215}.
CC   -!- FUNCTION: [Isoform 2]: Functions in the regulation of cell cycle
CC       progression through proteolytic processing of the CUX1 transcription
CC       factor (PubMed:15099520). Translation initiation at downstream start
CC       sites allows the synthesis of isoforms that are devoid of a signal
CC       peptide and localize to the nucleus where they cleave the CUX1
CC       transcription factor and modify its DNA binding properties
CC       (PubMed:15099520). {ECO:0000269|PubMed:15099520}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Specificity close to that of papain. As compared to cathepsin
CC         B, cathepsin L exhibits higher activity toward protein substrates,
CC         but has little activity on Z-Arg-Arg-NHMec, and no peptidyl-
CC         dipeptidase activity.; EC=3.4.22.15;
CC         Evidence={ECO:0000269|PubMed:9468501};
CC   -!- ACTIVITY REGULATION: Inhibited by the propeptide produced by
CC       autocleavage (PubMed:9468501). Long isoform of CD74/Ii chain stabilizes
CC       the conformation of mature CTSL by binding to its active site and
CC       serving as a chaperone to help maintain a pool of mature enzyme in
CC       endocytic compartments and extracellular space of APCs. IFNG enhances
CC       the conversion into the CTSL mature and active form (By similarity).
CC       Inhibited by CST6. Inhibited by the glycopeptide antibiotic teicoplanin
CC       (PubMed:26953343). Inhibited by amantadine (PubMed:32361028).
CC       {ECO:0000250|UniProtKB:P06797, ECO:0000269|PubMed:26953343,
CC       ECO:0000269|PubMed:30425301, ECO:0000269|PubMed:32361028,
CC       ECO:0000269|PubMed:9468501}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 5.5, also active at pH 7.0 with CUX1 as substrate.
CC         {ECO:0000269|PubMed:10716919, ECO:0000269|PubMed:15099520,
CC         ECO:0000269|PubMed:18562523, ECO:0000269|PubMed:9468501};
CC   -!- SUBUNIT: Dimer of a heavy and a light chain linked by disulfide bonds.
CC       Interacts with Long isoform of CD74/Ii chain; the interaction
CC       stabilizes the conformation of mature CTSL.
CC       {ECO:0000250|UniProtKB:P06797}.
CC   -!- INTERACTION:
CC       P07711; O60911: CTSV; NbExp=3; IntAct=EBI-1220160, EBI-1549974;
CC       P07711; O43765: SGTA; NbExp=3; IntAct=EBI-1220160, EBI-347996;
CC       P07711; P0DTC2: S; Xeno; NbExp=3; IntAct=EBI-1220160, EBI-25474821;
CC       P07711; P59594: S; Xeno; NbExp=2; IntAct=EBI-1220160, EBI-15582614;
CC       P07711; G5EFH4: srp-6; Xeno; NbExp=2; IntAct=EBI-1220160, EBI-1549936;
CC   -!- SUBCELLULAR LOCATION: Lysosome {ECO:0000250|UniProtKB:P06797}. Apical
CC       cell membrane {ECO:0000250|UniProtKB:P06797}; Peripheral membrane
CC       protein {ECO:0000250|UniProtKB:P06797}; Extracellular side
CC       {ECO:0000250|UniProtKB:P06797}. Cytoplasmic vesicle, secretory vesicle,
CC       chromaffin granule {ECO:0000250|UniProtKB:P25975}. Secreted,
CC       extracellular space {ECO:0000250|UniProtKB:P06797}. Secreted
CC       {ECO:0000250|UniProtKB:P06797}. Note=Localizes to the apical membrane
CC       of thyroid epithelial cells. Released at extracellular space by
CC       activated dendritic cells and macrophages.
CC       {ECO:0000250|UniProtKB:P06797}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Nucleus
CC       {ECO:0000269|PubMed:15099520}. Note=Translation initiation at
CC       downstream start sites allows the synthesis of isoforms that are devoid
CC       of a signal peptide and do not transit through the endoplasmic
CC       reticulum to localize to the nucleus (PubMed:15099520). Nuclear
CC       location varies during the cell cycle, with higher levels during S
CC       phase (PubMed:15099520). {ECO:0000269|PubMed:15099520}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1;
CC         IsoId=P07711-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P07711-3; Sequence=VSP_060720;
CC   -!- PTM: During export along the endocytic pathway, pro-CTSL undergoes
CC       several proteolytic cleavages to generate the CTSL single-chain and
CC       two-chain mature forms, composed of a heavy chain linked to a light
CC       chain by disulfide bonds (By similarity). Autocleavage; produces the
CC       single-chain CTSL after cleavage of the propeptide. The cleavage can be
CC       intermolecular (PubMed:9468501). {ECO:0000250|UniProtKB:P06797,
CC       ECO:0000269|PubMed:9468501}.
CC   -!- SIMILARITY: Belongs to the peptidase C1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU10088, ECO:0000255|PROSITE-ProRule:PRU10089,
CC       ECO:0000255|PROSITE-ProRule:PRU10090}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/40208/CTSL1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12451; CAA30981.1; -; mRNA.
DR   EMBL; M20496; AAA66974.1; -; mRNA.
DR   EMBL; CR457053; CAG33334.1; -; mRNA.
DR   EMBL; BX537395; CAD97637.1; -; mRNA.
DR   EMBL; AL160279; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012612; AAH12612.1; -; mRNA.
DR   EMBL; X05256; CAA28877.1; -; mRNA.
DR   CCDS; CCDS6675.1; -. [P07711-1]
DR   CCDS; CCDS94433.1; -. [P07711-3]
DR   PIR; S01002; KHHUL.
DR   RefSeq; NP_001244900.1; NM_001257971.1. [P07711-1]
DR   RefSeq; NP_001244901.1; NM_001257972.1. [P07711-1]
DR   RefSeq; NP_001903.1; NM_001912.4. [P07711-1]
DR   RefSeq; NP_666023.1; NM_145918.2. [P07711-1]
DR   RefSeq; XP_005251773.1; XM_005251716.3.
DR   PDB; 1CJL; X-ray; 2.20 A; A=22-333.
DR   PDB; 1CS8; X-ray; 1.80 A; A=19-333.
DR   PDB; 1ICF; X-ray; 2.00 A; A/C=114-288, B/D=292-333.
DR   PDB; 1MHW; X-ray; 1.90 A; A/B=114-288, C/D=292-333.
DR   PDB; 2NQD; X-ray; 1.75 A; B=113-333.
DR   PDB; 2VHS; X-ray; 1.50 A; A/B/C/D=114-333.
DR   PDB; 2XU1; X-ray; 1.45 A; A/B/C/D=114-333.
DR   PDB; 2XU3; X-ray; 0.90 A; A=114-333.
DR   PDB; 2XU4; X-ray; 1.12 A; A=114-333.
DR   PDB; 2XU5; X-ray; 1.60 A; A=114-333.
DR   PDB; 2YJ2; X-ray; 1.15 A; A=114-333.
DR   PDB; 2YJ8; X-ray; 1.30 A; A=114-333.
DR   PDB; 2YJ9; X-ray; 1.35 A; A=114-333.
DR   PDB; 2YJB; X-ray; 1.40 A; A=114-333.
DR   PDB; 2YJC; X-ray; 1.14 A; A=114-333.
DR   PDB; 3BC3; X-ray; 2.20 A; A/B=114-333.
DR   PDB; 3H89; X-ray; 2.50 A; A/B/C/D/E/F=114-333.
DR   PDB; 3H8B; X-ray; 1.80 A; A/B/C/D/E/F=114-333.
DR   PDB; 3H8C; X-ray; 2.50 A; A/B=114-333.
DR   PDB; 3HHA; X-ray; 1.27 A; A/B/C/D=114-333.
DR   PDB; 3HWN; X-ray; 2.33 A; A/B/C/D=76-333.
DR   PDB; 3IV2; X-ray; 2.20 A; A/B=114-333.
DR   PDB; 3K24; X-ray; 2.50 A; A/B=114-333.
DR   PDB; 3KSE; X-ray; 1.71 A; A/B/C=114-333.
DR   PDB; 3OF8; X-ray; 2.20 A; A=113-333.
DR   PDB; 3OF9; X-ray; 1.76 A; A=113-333.
DR   PDB; 4AXL; X-ray; 1.92 A; A=114-333.
DR   PDB; 4AXM; X-ray; 2.80 A; A/B/F/I/L/O=114-333.
DR   PDB; 5F02; X-ray; 1.43 A; A=114-333.
DR   PDB; 5I4H; X-ray; 1.42 A; A=113-218, B=222-333.
DR   PDB; 5MAE; X-ray; 1.00 A; A=114-333.
DR   PDB; 5MAJ; X-ray; 1.00 A; A=114-333.
DR   PDB; 5MQY; X-ray; 1.13 A; A=114-333.
DR   PDB; 6EZP; X-ray; 1.37 A; A=114-333.
DR   PDB; 6EZX; X-ray; 2.34 A; A/B=114-333.
DR   PDB; 6F06; X-ray; 2.02 A; A/B=114-333.
DR   PDB; 6JD0; X-ray; 1.80 A; A=18-333.
DR   PDB; 6JD8; X-ray; 1.46 A; A=18-333.
DR   PDB; 7QKB; X-ray; 1.80 A; A/B/C/D=114-333.
DR   PDB; 7QKC; X-ray; 1.69 A; A/B/C/D=114-333.
DR   PDB; 7QKD; X-ray; 1.50 A; A/B/C/D=114-333.
DR   PDB; 7W33; X-ray; 2.39 A; A=1-333.
DR   PDB; 7W34; X-ray; 2.89 A; A=1-333.
DR   PDB; 7Z3T; X-ray; 1.60 A; A/B/C/D=114-333.
DR   PDB; 7Z58; X-ray; 1.35 A; A/B/C/D=114-333.
DR   PDB; 7ZS7; X-ray; 1.60 A; A/B/C/D=114-333.
DR   PDB; 7ZVF; X-ray; 1.60 A; A/B/C/D=114-333.
DR   PDB; 7ZXA; X-ray; 1.60 A; A/B/C/D=114-333.
DR   PDB; 8A4U; X-ray; 1.90 A; A/B/C/D=114-333.
DR   PDB; 8A4V; X-ray; 1.65 A; A/B/C/D=114-333.
DR   PDB; 8A4W; X-ray; 1.40 A; A/B/C/D=114-333.
DR   PDB; 8A4X; X-ray; 1.80 A; A/B/C/D=114-333.
DR   PDB; 8A5B; X-ray; 1.80 A; A/B/C/D=114-333.
DR   PDB; 8AHV; X-ray; 1.70 A; A/B/C/D=114-333.
DR   PDB; 8B4F; X-ray; 1.90 A; A/B/C/D=114-333.
DR   PDB; 8C77; X-ray; 1.70 A; A/B/C/D=114-333.
DR   PDB; 8GX2; X-ray; 2.00 A; A/B=1-333.
DR   PDB; 8HET; X-ray; 2.00 A; A=114-333.
DR   PDB; 8HFV; X-ray; 2.10 A; A/B/C/D=114-333.
DR   PDB; 8OFA; X-ray; 1.90 A; A/B/C/D=114-333.
DR   PDB; 8OZA; X-ray; 1.80 A; A/B/C/D=114-333.
DR   PDB; 8PRX; X-ray; 1.80 A; A/B/C/D=114-333.
DR   PDB; 8QKB; X-ray; 1.60 A; A/B/C/D=114-333.
DR   PDB; 8UAC; X-ray; 1.40 A; A/B=114-333.
DR   PDBsum; 1CJL; -.
DR   PDBsum; 1CS8; -.
DR   PDBsum; 1ICF; -.
DR   PDBsum; 1MHW; -.
DR   PDBsum; 2NQD; -.
DR   PDBsum; 2VHS; -.
DR   PDBsum; 2XU1; -.
DR   PDBsum; 2XU3; -.
DR   PDBsum; 2XU4; -.
DR   PDBsum; 2XU5; -.
DR   PDBsum; 2YJ2; -.
DR   PDBsum; 2YJ8; -.
DR   PDBsum; 2YJ9; -.
DR   PDBsum; 2YJB; -.
DR   PDBsum; 2YJC; -.
DR   PDBsum; 3BC3; -.
DR   PDBsum; 3H89; -.
DR   PDBsum; 3H8B; -.
DR   PDBsum; 3H8C; -.
DR   PDBsum; 3HHA; -.
DR   PDBsum; 3HWN; -.
DR   PDBsum; 3IV2; -.
DR   PDBsum; 3K24; -.
DR   PDBsum; 3KSE; -.
DR   PDBsum; 3OF8; -.
DR   PDBsum; 3OF9; -.
DR   PDBsum; 4AXL; -.
DR   PDBsum; 4AXM; -.
DR   PDBsum; 5F02; -.
DR   PDBsum; 5I4H; -.
DR   PDBsum; 5MAE; -.
DR   PDBsum; 5MAJ; -.
DR   PDBsum; 5MQY; -.
DR   PDBsum; 6EZP; -.
DR   PDBsum; 6EZX; -.
DR   PDBsum; 6F06; -.
DR   PDBsum; 6JD0; -.
DR   PDBsum; 6JD8; -.
DR   PDBsum; 7QKB; -.
DR   PDBsum; 7QKC; -.
DR   PDBsum; 7QKD; -.
DR   PDBsum; 7W33; -.
DR   PDBsum; 7W34; -.
DR   PDBsum; 7Z3T; -.
DR   PDBsum; 7Z58; -.
DR   PDBsum; 7ZS7; -.
DR   PDBsum; 7ZVF; -.
DR   PDBsum; 7ZXA; -.
DR   PDBsum; 8A4U; -.
DR   PDBsum; 8A4V; -.
DR   PDBsum; 8A4W; -.
DR   PDBsum; 8A4X; -.
DR   PDBsum; 8A5B; -.
DR   PDBsum; 8AHV; -.
DR   PDBsum; 8B4F; -.
DR   PDBsum; 8C77; -.
DR   PDBsum; 8GX2; -.
DR   PDBsum; 8HET; -.
DR   PDBsum; 8HFV; -.
DR   PDBsum; 8OFA; -.
DR   PDBsum; 8OZA; -.
DR   PDBsum; 8PRX; -.
DR   PDBsum; 8QKB; -.
DR   PDBsum; 8UAC; -.
DR   AlphaFoldDB; P07711; -.
DR   SMR; P07711; -.
DR   BioGRID; 107894; 233.
DR   IntAct; P07711; 33.
DR   MINT; P07711; -.
DR   STRING; 9606.ENSP00000345344; -.
DR   BindingDB; P07711; -.
DR   ChEMBL; CHEMBL3837; -.
DR   DrugBank; DB07477; Felbinac.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB03661; L-cysteic acid.
DR   DrugBank; DB14962; Trastuzumab deruxtecan.
DR   DrugCentral; P07711; -.
DR   GuidetoPHARMACOLOGY; 2351; -.
DR   MEROPS; C01.032; -.
DR   MEROPS; I29.001; -.
DR   GlyConnect; 1081; 12 N-Linked glycans (1 site).
DR   GlyCosmos; P07711; 2 sites, 14 glycans.
DR   GlyGen; P07711; 3 sites, 13 N-linked glycans (1 site), 1 O-linked glycan (2 sites).
DR   iPTMnet; P07711; -.
DR   PhosphoSitePlus; P07711; -.
DR   BioMuta; CTSL; -.
DR   DMDM; 115741; -.
DR   jPOST; P07711; -.
DR   MassIVE; P07711; -.
DR   PaxDb; 9606-ENSP00000345344; -.
DR   PeptideAtlas; P07711; -.
DR   ProteomicsDB; 52023; -.
DR   Pumba; P07711; -.
DR   ABCD; P07711; 1 sequenced antibody.
DR   Antibodypedia; 4374; 748 antibodies from 39 providers.
DR   DNASU; 1514; -.
DR   Ensembl; ENST00000340342.11; ENSP00000365061.5; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000343150.10; ENSP00000345344.5; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000676480.1; ENSP00000504279.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000676531.1; ENSP00000503439.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000676769.1; ENSP00000504405.1; ENSG00000135047.16. [P07711-3]
DR   Ensembl; ENST00000676881.1; ENSP00000502901.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000676946.1; ENSP00000503470.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000677019.1; ENSP00000504473.1; ENSG00000135047.16. [P07711-3]
DR   Ensembl; ENST00000677262.1; ENSP00000503851.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000677761.1; ENSP00000503938.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000677821.1; ENSP00000503298.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000677864.1; ENSP00000503881.1; ENSG00000135047.16. [P07711-3]
DR   Ensembl; ENST00000678442.1; ENSP00000503897.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000679149.1; ENSP00000504313.1; ENSG00000135047.16. [P07711-1]
DR   Ensembl; ENST00000679157.1; ENSP00000502968.1; ENSG00000135047.16. [P07711-1]
DR   GeneID; 1514; -.
DR   KEGG; hsa:1514; -.
DR   MANE-Select; ENST00000343150.10; ENSP00000345344.5; NM_001912.5; NP_001903.1.
DR   UCSC; uc004aph.4; human. [P07711-1]
DR   AGR; HGNC:2537; -.
DR   CTD; 1514; -.
DR   DisGeNET; 1514; -.
DR   GeneCards; CTSL; -.
DR   HGNC; HGNC:2537; CTSL.
DR   HPA; ENSG00000135047; Tissue enhanced (placenta).
DR   MIM; 116880; gene.
DR   neXtProt; NX_P07711; -.
DR   OpenTargets; ENSG00000135047; -.
DR   PharmGKB; PA162382890; -.
DR   VEuPathDB; HostDB:ENSG00000135047; -.
DR   eggNOG; KOG1543; Eukaryota.
DR   GeneTree; ENSGT00940000154367; -.
DR   HOGENOM; CLU_012184_1_2_1; -.
DR   InParanoid; P07711; -.
DR   OMA; VYYDEEC; -.
DR   OrthoDB; 5472948at2759; -.
DR   PhylomeDB; P07711; -.
DR   TreeFam; TF313739; -.
DR   BRENDA; 3.4.22.15; 2681.
DR   BRENDA; 3.4.22.43; 2681.
DR   BRENDA; 3.4.22.B49; 2681.
DR   PathwayCommons; P07711; -.
DR   Reactome; R-HSA-1236977; Endosomal/Vacuolar pathway.
DR   Reactome; R-HSA-1442490; Collagen degradation.
DR   Reactome; R-HSA-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-HSA-1679131; Trafficking and processing of endosomal TLR.
DR   Reactome; R-HSA-2022090; Assembly of collagen fibrils and other multimeric structures.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-8939242; RUNX1 regulates transcription of genes involved in differentiation of keratinocytes.
DR   Reactome; R-HSA-9678110; Attachment and Entry.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   SignaLink; P07711; -.
DR   SIGNOR; P07711; -.
DR   BioGRID-ORCS; 1514; 28 hits in 1168 CRISPR screens.
DR   ChiTaRS; CTSL; human.
DR   EvolutionaryTrace; P07711; -.
DR   GeneWiki; Cathepsin_L1; -.
DR   GenomeRNAi; 1514; -.
DR   Pharos; P07711; Tclin.
DR   PRO; PR:P07711; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P07711; protein.
DR   Bgee; ENSG00000135047; Expressed in stromal cell of endometrium and 214 other cell types or tissues.
DR   ExpressionAtlas; P07711; baseline and differential.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042583; C:chromaffin granule; ISS:UniProtKB.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0071682; C:endocytic vesicle lumen; TAS:Reactome.
DR   GO; GO:0036021; C:endolysosome lumen; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005771; C:multivesicular body; IDA:ARUK-UCL.
DR   GO; GO:0005634; C:nucleus; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0005518; F:collagen binding; IDA:BHF-UCL.
DR   GO; GO:0008656; F:cysteine-type endopeptidase activator activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008234; F:cysteine-type peptidase activity; IDA:UniProtKB.
DR   GO; GO:0001968; F:fibronectin binding; IPI:BHF-UCL.
DR   GO; GO:0042393; F:histone binding; IDA:BHF-UCL.
DR   GO; GO:0043394; F:proteoglycan binding; IPI:BHF-UCL.
DR   GO; GO:0097655; F:serpin family protein binding; IPI:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEP:UniProtKB.
DR   GO; GO:0019882; P:antigen processing and presentation; TAS:UniProtKB.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0048002; P:antigen processing and presentation of peptide antigen; ISS:UniProtKB.
DR   GO; GO:0043373; P:CD4-positive, alpha-beta T cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0030574; P:collagen catabolic process; IDA:UniProtKB.
DR   GO; GO:0060309; P:elastin catabolic process; ISS:UniProtKB.
DR   GO; GO:0034230; P:enkephalin processing; ISS:UniProtKB.
DR   GO; GO:0039654; P:fusion of virus membrane with host endosome membrane; IDA:UniProtKB.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0071888; P:macrophage apoptotic process; NAS:BHF-UCL.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IBA:GO_Central.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:UniProtKB.
DR   GO; GO:0006508; P:proteolysis; IDA:UniProtKB.
DR   GO; GO:0051603; P:proteolysis involved in protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0019065; P:receptor-mediated endocytosis of virus by host cell; IDA:UniProtKB.
DR   GO; GO:0046718; P:symbiont entry into host cell; IDA:UniProtKB.
DR   GO; GO:0031638; P:zymogen activation; IDA:UniProtKB.
DR   CDD; cd02248; Peptidase_C1A; 1.
DR   Gene3D; 3.90.70.10; Cysteine proteinases; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR025661; Pept_asp_AS.
DR   InterPro; IPR000169; Pept_cys_AS.
DR   InterPro; IPR025660; Pept_his_AS.
DR   InterPro; IPR013128; Peptidase_C1A.
DR   InterPro; IPR000668; Peptidase_C1A_C.
DR   InterPro; IPR039417; Peptidase_C1A_papain-like.
DR   InterPro; IPR013201; Prot_inhib_I29.
DR   PANTHER; PTHR12411; CYSTEINE PROTEASE FAMILY C1-RELATED; 1.
DR   PANTHER; PTHR12411:SF902; PROCATHEPSIN L; 1.
DR   Pfam; PF08246; Inhibitor_I29; 1.
DR   Pfam; PF00112; Peptidase_C1; 1.
DR   PRINTS; PR00705; PAPAIN.
DR   SMART; SM00848; Inhibitor_I29; 1.
DR   SMART; SM00645; Pept_C1; 1.
DR   SUPFAM; SSF54001; Cysteine proteinases; 1.
DR   PROSITE; PS00640; THIOL_PROTEASE_ASN; 1.
DR   PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR   PROSITE; PS00639; THIOL_PROTEASE_HIS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Cell membrane; Cytoplasmic vesicle;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Host-virus interaction; Hydrolase; Lysosome; Membrane; Nucleus; Protease;
KW   Proteomics identification; Reference proteome; Secreted; Signal;
KW   Thiol protease; Zymogen.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000250|UniProtKB:P07154"
FT   PROPEP          18..113
FT                   /note="Activation peptide"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT                   /id="PRO_0000026244"
FT   CHAIN           114..333
FT                   /note="Cathepsin L"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT                   /id="PRO_0000450791"
FT   CHAIN           114..288
FT                   /note="Cathepsin L heavy chain"
FT                   /id="PRO_0000026245"
FT   PROPEP          289..291
FT                   /id="PRO_0000026246"
FT   CHAIN           292..333
FT                   /note="Cathepsin L light chain"
FT                   /evidence="ECO:0000269|PubMed:3545185"
FT                   /id="PRO_0000026247"
FT   ACT_SITE        138
FT                   /evidence="ECO:0000305|PubMed:9468501"
FT   ACT_SITE        276
FT   ACT_SITE        300
FT   SITE            106..107
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            107..108
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            112..113
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   SITE            113..114
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   CARBOHYD        221
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519,
FT                   ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:19159218"
FT   DISULFID        135..178
FT                   /evidence="ECO:0000269|PubMed:8896443,
FT                   ECO:0007744|PDB:1CJL, ECO:0007744|PDB:1CS8"
FT   DISULFID        169..211
FT                   /evidence="ECO:0000269|PubMed:8896443,
FT                   ECO:0007744|PDB:1CJL, ECO:0007744|PDB:1CS8"
FT   DISULFID        269..322
FT                   /note="Interchain (between heavy and light chains)"
FT                   /evidence="ECO:0000269|PubMed:8896443,
FT                   ECO:0007744|PDB:1CJL, ECO:0007744|PDB:1CS8"
FT   VAR_SEQ         1..55
FT                   /note="Missing (in isoform 2)"
FT                   /id="VSP_060720"
FT   MUTAGEN         138
FT                   /note="C->S: Catalytically inactive. Unable to autocleave
FT                   procathepsin L."
FT                   /evidence="ECO:0000269|PubMed:9468501"
FT   CONFLICT        56
FT                   /note="M -> V (in Ref. 6; AAH12612)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268
FT                   /note="D -> N (in Ref. 7; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..25
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   HELIX           26..35
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   TURN            42..44
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   HELIX           45..67
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   STRAND          72..75
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   TURN            79..82
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   HELIX           85..91
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   STRAND          103..105
FT                   /evidence="ECO:0007829|PDB:6JD8"
FT   STRAND          116..119
FT                   /evidence="ECO:0007829|PDB:6EZX"
FT   HELIX           120..123
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          134..136
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           138..155
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           163..169
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   TURN            171..174
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:2XU4"
FT   HELIX           183..193
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          196..198
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   TURN            199..201
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           215..217
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          218..220
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          223..227
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           232..241
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          245..249
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           254..257
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:4AXL"
FT   STRAND          276..285
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          289..291
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          294..299
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:6EZP"
FT   TURN            307..309
FT                   /evidence="ECO:0007829|PDB:7W34"
FT   STRAND          311..315
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          317..320
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   HELIX           321..323
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   TURN            324..326
FT                   /evidence="ECO:0007829|PDB:2XU3"
FT   STRAND          329..332
FT                   /evidence="ECO:0007829|PDB:2XU3"
SQ   SEQUENCE   333 AA;  37564 MW;  8CD17D00EF859D85 CRC64;
     MNPTLILAAF CLGIASATLT FDHSLEAQWT KWKAMHNRLY GMNEEGWRRA VWEKNMKMIE
     LHNQEYREGK HSFTMAMNAF GDMTSEEFRQ VMNGFQNRKP RKGKVFQEPL FYEAPRSVDW
     REKGYVTPVK NQGQCGSCWA FSATGALEGQ MFRKTGRLIS LSEQNLVDCS GPQGNEGCNG
     GLMDYAFQYV QDNGGLDSEE SYPYEATEES CKYNPKYSVA NDTGFVDIPK QEKALMKAVA
     TVGPISVAID AGHESFLFYK EGIYFEPDCS SEDMDHGVLV VGYGFESTES DNNKYWLVKN
     SWGEEWGMGG YVKMAKDRRN HCGIASAASY PTV
//